ABSTRACT. Strategies for hepatic gene therapy have been proposed that involve isolation of primary hepatocytes and introduction of recombinant genes into these cells in culture, followed by autologous hepatocellular transplantation (HCT). Consideration of clinical applications requires data suggesting that HCT can be performed safely in human subjects in addition to data indicating that recombinant gene expression can reverse a disease process. This report describes preclinical studies that underlie a clinical trial of HCT in which hepatocytes would be labeled with a marker gene to facilitate assessment of engraftment in the recipient. Human hepatocytes were harvested from liver segments preserved in Belzar's solution and transduced with an amphotropic retroviral vector carrying a recombinant marker gene (neomycin phosphotransferase 11). Human hepatocytes were recovered from monolayer culture, stained with the fluorescent dye 1,l'-dioctadecyl-3,3,3,3'-tetra-methylindo-carbocyanine perchlorate (DiI) and transplanted into severe combined immunodeficient mice by splenic injection. Engrafted hepatocytes were identified in the liver and spleen of severe combined immunodeficient mice but not immunocompetent controls. Two large animal models of HCT are described. In a dog model, neomycin phosphotransferase 11-containing hepatocytes were identified in the liver 7 wk after transplantation. In a baboon model, autologous H a with DiI-stained cells demonstrated that transplanted cells assume a normal morphology and constitute up to 5% of hepatocytes. These data demonstrate transduction and transplantation of human hepatocytes and the feasibility of HCT in large animals.
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On the basis of these studies, the proposed clinical trial for gene transfer and transplantation in human subjects has been approved by the National Institutes of Health and the Food and Drug Administration. These studies illustrate the nature and extent of preclinical data required to gain approval for clinical trials involving gene transfer into human subjects. These data also illustrate the limitations of existing methods that may be used for hepatic gene therapy in the future. (Pediatr Res 33: 313-320, 1993) Abbreviations H a , hepatocellular transplantation AAT, crl-antitrypsin DiI, 1,1'-dioctadecyl-3,3,3,3'-tetra-methylindo-carbocyanine perchlorate; DiI-Cia-(3) SCID, severe combined immunodeficient NEO-R, neomycin phosphotransferase 11, neomycin resistance gene OLT, orthotopic liver transplantation PCR, polymerase chain reaction NIH, National Institutes of Health &gal, j3-galactosidase
The potential for somatic gene therapy is based on methods for gene transfer in which recombinant genes are introduced into somatic cells to reconstitute expression of a genetically defective gene or constitute expression of a novel therapeutic gene (1-3). One strategy for somatic gene therapy involves harvesting primary cells from a patient. growing these cells in culture. transducing these cells ex vivo with a vector containing a recombinant gene. and returning these cells to the patient by autologous transplantation.
With the initiation of clinical trials at the NIH involving gene deliverv into patients after ex viva gene transfer of autologous ' These data were described in public hearings of the Human Gene Therapy lymph&yte pbpulations. it is now possible to realistically con- LEDLEY therapy to hepatic diseases requires not only the demonstration that genes can be introduced into primary hepatocytes in culture (4) (5) (6) (7) (8) but also the ability to perform HCT. a procedure that has never been performed in human subjects (9) .
Research in our laboratories has been directed at developing methods for hepatic gene therapy. Perhaps the most difficult aspect of this research has been establishing the feasibility of HCT. There is extensive literature on animal experiments that suggests that HCT can be performed successfully in small animal models (lo. 1 1). Nevertheless, there remains considerable uncertainty about the feasibility of HCT. One of the reasons HCT has not been more widely accepted is that many early animal studies were not able to unequivocally demonstrate the location and number of engrafted cells after transplantation. Heterotopic engraftment of hepatocytes has been demonstrated in the peritoneum, portal vein. spleen, fat pads, pancreas, or dorsal fascia, where the characteristic morphology of hepatocytes is recognizable by conventional histologic techniques (10, I 1). Recent studies have used transgenic mice containing recombinant genetic markers to demonstrate engraftment of hepatocytes within the hepatic parenchyma after intraportal or intrasplenic injection. Ponder et a/. (9) ( 14, 15) .
T o assess the feasibility of HCT in human subjects and establish a clinical foundation for future experiments involving hepatic gene therapy, we have proposed a phase I clinical trial of HCT in children with life-threatening hepatic insufficiency who have no other medical or surgical options. Heterologous HCT represents a potentially important therapeutic modality that, by itself, may have applications in the treatment of hepatic insufficiency, especially in children, for whom there is a chronic shortage of donor organs and a 20 to 50% mortality rate (16) (17) (18) (19) (20) . In experimental animals, HCT has been shown to improve survival in hepatic failure in mice or dogs induced by N-galactosamine, dimethylnitrosamine, or surgery (2 1-28). Our expectation is that HCT may provide short-term hepatic support for patients awaiting OLT, a "bridge to recovery" for patients with infectious hepatitis. or a long-term repopulation of the patient's liver with healthy donor cells (29) .
T o rigorously evaluate the success of hepatocellular engraftment, we proposed introducing a recombinant marker gene, NEO-R, into hepatocytes by transduction with a retroviral vector (LNL6) before transplantation. The presence of this genetic marker in transplanted cells will enable a quantitative determination of the number of cells engrafting in the liver and their persistence.
There continues to be controversy concerning the propriety of clinical trials involving gene transfer as well as the extent and nature of in vitro and animal studies that should be performed before clinical trials should begin. This report describes the preclinical data, concerning gene transfer into human hepatocytes and HCT in animal models, that were submitted to the Human Gene Therapy Subcommittee, Recombinant Advisory Committee, Director of the NIH, and b-ood and Drug Administration in support of our proposed clinical trial. This report is intended both to demonstrate the capabilities and limitations of current technologies for ex vivo hepatic gene therapy and to illustrate the nature and extent of preclinical studies that led to approval for a clinical trial involving gene transfer into the liver of human subjects (Federal Regi.7tc .r. July 18. 199 1 ).
METHODS AND RESULTS

Han~est and cultir~ation of human hepatoq~tes. Human liver
segments preserved in UW solution (30) were made available by the "Liver Tissue Procurement and Distribution System'' (3 1). Hepatocytes were harvested from the right lobes of the liver that were available after reduced OLT or from organs that had evidence of anoxia. which made them unsuitable for OLT. Hepatocytes were isolated using variations of procedures described previously (9, 32, 33) . Liver segments were perfused sequentially with EDTA solution (Earle's balanced salt solution without Ca'+. Mg" + 0.5 mM EDTA) followed by collagenase solution [Earle's balanced salt solution with Ca++, Mg". 180 mg/400 mL collagenase B (Boehringer Mannheim. Mannheim. Germany). 8 mg/400 mL soybean trypsin inhibitor] for 15 min each at 37°C. Hepatocytes were then physically separated by gentle shaking in collagenase solution, filtered through sterile gauze, washed, and plated on Primaria plates at densities of 2 X 104/cm2 in media with 10% serum (34) . After 8 to 24 h. medium was replaced with a hormonally defined medium (SUM-Chowdhury). similar to those used previously to maintain the state of differentiation and the proliferation potential of mature hepatocytes (33-35) but adapted to optimize the morphology of human hepatocytes [SUM-Chowdhury medium: 3: 1, minimum essential medium: weymouths (tyrosine-free), insulin, 1.7 x lo-* M (100 ng/mL): glucagon, 2.8 x M ( 1 pg/mL): epidermal growth factor, 8.3 x M (50 ng/mL): somatotropin. 9.5 x 10-I' M ( 10 pU/mL); linoleic acid, 1.8 x IW5 M (5 pg/mL); selenium, 3 nM; N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (pH 7.4), 10 mM; dexamethasone, M: thyroxine. I pM: transfenin. 1.3 x lo-' M (10 pg/mL): Gly-His-Lys. 6.5 x lo-* M (20 ng/mL)]. Tyrosine-free medium was used to select against the proliferation of fibroblasts, endothelial cells. or dedifferentiated hepatocytes that might lose expression on phenylalanine hydroxylase.
Hepatocytes were harvested from 18 livers. Hepatocyte yields from appropriately preserved and histologically normal livers ranged from 2.7 to 10 x 106/g with 75 to 95% viability by trypan blue exclusion and plating efficiencies of 60 to 90%. Cells surviving in this culture medium exhibited the morphology of hepatocytes, and cells plated at a density of 4 x lo4 cells/cm2 grew to confluence within 4 d in tyrosine-free, hormonally defined medium (34) . lmmunohistochemical staining for AAT or glutamine synthase demonstrated that >99% of the cells in culture express these liver-specific products (34) . Extremely poor yields were obtained from livers with evidence of fatty infiltration or inadequate preservation.
These experiments demonstrated that human hepatocytes could be isolated from liver samples procured under clinically applicable conditions, proliferated in hormonally defined media, and still preserve properties characteristic of differentiated hepatocytes.
Retroviral transduction. The LNL6 vector containing the E. coli NEO-R gene and a cell line, LNL6/PA3 171~8, producing amphotropic LNL6, were constructed by Dr. Dusty Miller in the PA317 cell line (36, 37). Frozen lots of supernatant from this cell line, certified for clinical applications, were provided by Genetic Therapy Inc., Gaithersburg, MD. A vector containing the E. coli 0-gal gene (zen-0-gal) was provided by Dr. Philippe Soriano (Baylor College of Medicine). Hepatocytes were transduced by replacing the culture media with a 1:l dilution of serum-free mediaxetroviral supernatant with 8 pg/mL polybrene between 24 and 72 h after harvest. Cells were maintained in hormonally defined, tyrosine-free media for 8 d after transduction (10 d after harvest) before analysis was performed.
Hepatocytes transduced with the 0-gal-containing vectors were ' a set of primers that recognize the MUT locus to rule out variations in the quality or amount of the DNA template.
Comparison of experimental samples with the standard curve indicates that the efficiency of transduction was 1 to 3%. This efficiency was 10-fold lower than the efficiency in parallel experiments using mouse hepatocytes (Fig. IA) . Transduction of , human hepatocytes has also been described by Grossman et al. (39) .
After HCT. the transplanted cells will constitute only a fraction of the recipient's liver. To demonstrate that methods for PCR detection of the proviral sequences were suficiently sensitive to detect these sequences after transplantation. DNA from the transduced hepatocytes was diluted with nontransduced DNA (Fig. I B) and analyzed by PCR. Proviral sequences were detected at a 1:300 dilution, indicating that this method could detect engraftment constituting as little as 0.3% of cells in the liver.
Transplantation (?/'human cells in SCID and immunocompetent mice. Heterotopic transplantation of human hepatocytes has been described previously in athymic rats (40) and nude mice (4 1 ). To demonstrate that human hepatocytes recovered from culture by trypsinization were viable and capable of engrafting in the liver. transplants were performed with human cells in immunodeficient (SCID) or normal C57/BL-6 mice. In these experiments, the human hepatocytes were stained with the fluorescent dye DiI, which enables detection of transplanted cells in the recipient organ by fluorescence microscopy. This dye was originally developed for research in neurobiology, where it has been shown not to metabolize and does not exchange between cells. We have described optimal conditions for in vitro staining of hepatocytes with DiI and evidence that this dye remains localized to transplanted cells in vitro and after HCT in congenic animals (42. 43).
Human hepatocytes in culture were stained by addition of 2.7 x M DiI (25 pg/mL) + 1 % DMSO for 30 min, trypsinized. and washed. and 2 x 10' cells were infused into the spleen of normal or SCID animals. Animals were killed at 5 or 12 d after transplantation. All of the animals survived the transplant procedure. Three of six animals had areas of scamng in the liver as seen by gross examination. possibly due to infarction. Complete necropsy revealed no other significant abnormalities. Histologic examination of the liver in transplanted SCID animals showed normal architecture. Fluorescent hepatocytes could be identified in the liver (Fig. 3.4) and spleen ( These experiments indicate that human hepatocytes are viable and remain capable of engrafting within the hepatic parenchyma after cultivation and trypsinization. The lack of significant adverse events in immunodeficient animals also indicates that these procedures can be perfvrmecl wilhoul infectiuu~ cumpiicatiuns.
T~I L~ eficiency of HCT in mzrrine models. The clinical impact of HCT will be critically dependent upon the fraction of the host liver that can be constituted from the hepatocellular graft. In the murine model of Ponder 6. 1 al. (9) . two methods were used to estimate the number of transgenic hepatocytes engrafted in the liver. One estimate was based on the level of human AAT present in the serum of donor and recipient animals. This calculation places the fraction of engrafted cells at ranges from lo-' to 6 x (9). The second estimate. based on the number of cells expressing E. coli 0-gal on histochemical analysis. is complicated by the fact that in the donor mouse liver only 10% of cells express this transgene. The number of cells in the recipient that exhibit &gal staining ranges from 3 x to 5 x lo-'. If this number is corrected for the fraction of cells expressing this gene in the donors. then the fraction of engrafted cells is in the range of 3 x lo-' to 5 X which is concordant with the estimate made from the AAT data. It should be noted that this fraction is roughly consistent with the number of fluorescent cells observed after transplantation of human hepatocytes in SCID mice.
A similar efficiency of engraftment was apparent in experiments performed using syngeneic cells transduced with the LNL6 retroviral vector (Fig. 3.4) . In these experiments. cells were harvested. cultivated. transduced. and transplanted using the pro- A tion of dog hepatocytes with an amphotropic vector carrying both NEO-R and human AAT. Expression of human AAT was M A B C D 1 2 3 observed for several weeks after HCT and then was lost. PCR analysis of the liver from transplanted animals harvested 47 d after transplantation demonstrated that the recombinant provirus was evident in these samples (Fig. 3B) . indicating that viable cells remained in the liver even though there was no expression d l @ "#if#YB from the recombinant provirus (44).
The feasibility of HCT and intrahepatic engraftment was also studied in two baboons. For this experiment. a left-lateral partial hepatectomy was performed. and hepatocytes were isolated, stained with DiI. and injected into the spleen. One wk later, the animals were killed. Histologic examination showed normal architecture in the liver, with no evidence for a distinct population of transplanted cells (data not shown). Rare sections had B evidence of transplanted material within distal portal venule. a b c d e f g h i j k l m with no evidence of infarctions (Fig. 4A) . Fluorescent cells were seen throughout the hepatic parenchyma in two animals studied (Fig. 4B) . Histologic examination of the spleen showed hepatocytes (Fig. 4C ) that retained the fluorescent dye (Fig. 4 0 ) . To + quantify the number of donor cells in the liver, hepatocytes were isolated and fluorescent and nonfluorescent cells counted in digitized phase contrast and fluorescent images trom one animal (Fig. 4E , Table 1 ). These data demonstrate that 4. 
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injecting these cells into animals. HCT was also shown to constitute up to 5% of the hepatocvtes in the liver from donor cells, a portion that is >lo-fold greater than that observed in murine experiments. liver (1, 45) . This is particularly true of inborn errors of metabolism that may require replacement of defective genetic functions in cells that contain cofactors, heterologous subunits. or substrates that are essential for activity of the gene product (46) . Considerable progress has been made toward this goal with the development of methods for hepatocellular cultivation. transduction. and transplantation in small animal models (2-9. 12-15).
One premise of our approach to hepatic gene therapy is that the clinical feasibility of HCT needs to be established in clinical practice before it is applied in clinical trials of e.y vivo hepatic gene therapy. To this end. we have proposed a clinical trial of hepatocellular transplantation to assess the feasibility in human subjects (29) . In this clinical trial, we propose to mark allogenic hepatocytes with the LNL6 vector before transplantation and use the presence of this marker gene in the recipient organ to determine the number and location of engrafted cells. Societal and scientific concern about the propriety of clinical trials involving gene transfer led to the creation of a special process of ethical and scientific review of such trials. Proposed clinical trials of gene transfer are subject to review by the Human Gene Therapy Subcommittee, the Recombinant DNA Advisory Committee. and the director of the NIH. in addition to local Institutional Review Boards. Institutional Biosafety Committees. and the Food and Drug Administration.
Three general questions were posed by these committees in considering our proposal: "Is it safe?" "Is it feasible?" "Is it necessary?'' (47). These are the same questions that the scientific and medical community must ask in assessing whether clinical trials involving gene transfer are appropriate or whether such 318 LEDLEY ET AL. 
can be used safely in human subjects. It should also be noted that the absence of recognized human disease from the ubiquitous wild-type viruses related to Moloney murine leukemia virus provides further evidence that these agents are nonpathogenic in man (53). HCT itself will involve significant risks. Our studies in mice. dogs, and baboons provide evidence that the surgical aspects of HCT can be performed safely. Our studies with transplantation I of human hepatocytes into SCID mice indicate that these cells can be transplanted without toxicity or risk of infection to the subject. In addition. intensive efforts are essential to ensure that I the process of hepatocellular harvest, cultivation. transduction. and transplantation is subjected to stringent quality control and , quality assessment procedures as any other biologic product prepared for administration to humans would be.
Our preclinical data suggest that the HCT can be performed successfully. The ethical standards and federal regulations concerning clinical trials require that the relative risk of a clinical , trial be "reasonably commensurate" with the patient's disease and conventional therapy (in this protocol orthotopic hepatic transplantation) (54-57). Thus. the patient selection criteria that have been established (21) are essential in determining the relativc risk of the prcpcsed ?ril! as describe.' &sewhere.
Is ir.feasible.7 Most of the data described in this report address the issue of feasibility. The critical question is whether the provirus present in the small fraction of transduced and transplanted cells will be detectable in the recipient liver with existing assays. Figure 5 shows the fraction of cells that will contain the LNL6 provirus as a function of the transduction efficiency (xaxis. abscissa) and transplantation efficienc) (>-axis. ordinate). The shaded region shows the expected frequency of provirus in transplanted ~;~a n s based on these preclir&al data. The curves show the threshold of sensitivity for assays capable of detecting the provirus in and cells. This graph illustrates that with a level of sensitivity of it is reasonable to expect detection of proviral sequences in the study population.
This calculation also demonstrates the limitations of current methods for ex vivo gene delivery to the liver. For example, if successful gene therapy will require constitution of gene expression in >I % of hepatic cells. significantly improved transduction or transplantation technologies will be required.
Is it necessarj!?
We believe that it is important to establish the feasibility of HCT, the efficiency of engraftment. and the longev- duction a n d transplantation efficiency. T h e efficiency o f transduction (xaxis) a n d efficienc) of transplantation (y-axis) determines t h e fraction of cells in the recipient that will contain t h e recombinant provirus. T h e range of transduction a n d transplantation efficiency suggested by preclinical data is shown by t h e shaded region. T h e range o f detection is shown for assays with sensitivity of lo-'. a n d with everything t o the right of each curve being detectable.
ity of transplanted cells in careful clinical trials. It is not obvious that any available animal models represent quantitatively appropriate models for assessing the efficiency of transduction and transplantation in human subjects. and it is likely that there will be variation in the efficiency of these processes in different individuals based on age. diagnosis. or other factors. Thus, we believe there is no substitute for clinical data concerning hepatocyte transduction and transplantation. in conjunction with continuing animal studies on optimization and safety, before e s sivo gene therapy can be proposed with confidence.
This study was designed to assess methods for retrovirusmediated gene transfer in human subjects in a clinical situation in which the patient's well-being does not depend on the success of transduction or stable gene expression. This strategy was used previously by Rosenberg er al. (52) . who used gene marking of tumor-infiltrating lymphocytes to establish the feasibility and safety of gene transfer in human subjects before proceeding with therapeutic trials of gene therapy. Marker gene studies have provided critical data concerning the efficiency of retroviral transduction, the persistence of the proviral sequences in vivo. 
